You are here

Lipitor Provides Greater Reductions in Heart Attack, Stroke and Cardiovascular Procedures Compared to Zocor

NEW YORK, May 15 /PRNewswire-FirstCall/ -- Pfizer Inc said today that a new economic analysis that compares outcomes for patients taking Lipitor to those taking Zocor shows that Lipitor patients had greater reductions in heart attacks, strokes and cardiovascular procedures. This provides a cost savings for payors in long-term hospitalizations and surgical costs.

The economic analysis examined the results from the IDEAL (Incremental Decrease in Endpoints Through Aggressive Lipid Lowering) trial to analyze the cost effectiveness of treatment with Lipitor and Zocor (simvastatin) in Sweden, where Zocor is available generically as simvastatin. The IDEAL patients who received Lipitor (80 mg) achieved greater reductions in heart attacks, strokes and cardiovascular procedures compared to patients taking standard dose Zocor (20-40 mg).

The results also showed that one out of every six heart attacks, strokes or cardiovascular procedures could be avoided for coronary heart disease patients treated with intensive Lipitor therapy above and beyond those treated with Zocor over 4.8 years.

These results were then applied to the U.S. health care system, with two key findings:

* Better efficacy was achieved in patients taking Lipitor, at a better overall value, compared to patients on standard Zocor therapy; and

* Patients taking Lipitor achieved greater reductions in cardiovascular events, and the system had overall cost savings, compared to patients taking Zocor at the current U.S. price, and even when Zocor was discounted by 50 percent.

In the U.S., cardiovascular disease remains the nation's leading health threat, and accounts for an estimated 500,000 recurrent heart attacks and 200,000 recurrent debilitating strokes annually.

"The economic impact of heart attacks and strokes in the U.S. alone totals nearly $403 billion in medical care and lost productivity annually," said Dr. Peter Lindgren, Stockholm Health Economics. "This analysis suggests that the cost of using Lipitor versus generic simvastatin could represent a good value for money."

"Even if the current U.S. price of Zocor were reduced by 75 percent, Lipitor patients could still achieve better cardiovascular outcomes at an increase to payors of less than one dollar a day," said Dr. Gregg Larson, vice president cardiovascular medical at Pfizer. "While the economic cost of a stroke can be exorbitant, often entailing years of rehabilitation and supervised care the emotional impact on patients and their families is also devastating."

The IDEAL economic analysis assessed the cost-effectiveness of preventing cardiovascular events for patients who took intensive Lipitor therapy versus standard dose Zocor. The analysis compared the total cost per patient for 4.8 years in each treatment group by calculating medication costs, the cost of hospitalizations associated with cardiovascular events and lost work days for the U.S. and for Sweden. The cost of Lipitor was compared to the cost of generic simvastatin for Sweden. For the U.S., the cost of Lipitor was compared to Zocor in three scenarios, including:

* Lipitor compared to the current U.S. price of Zocor (simvastatin);

* Lipitor compared to a 50% reduction in the current U.S. price of Zocor; and

* Lipitor compared to a 75% reduction in the current U.S. price of Zocor.

"IDEAL, which is one of a limited number of head to head statin therapy trials showed that patients using intensive atorvastatin therapy compared with standard dose simvastatin suffered fewer cardiovascular events. The findings in IDEAL, along with other positive studies of intensive atorvastatin therapy against active treatment comparitors such as AVERT, PROVE-IT, REVERSAL and ALLIANCE, indicate that all statin therapy in not alike," said Dr. Michael Koren, director of non-invasive cardiology at Memorial Hospital in Jacksonville, Florida. "Switching patients from atorvastatin to other less effective drugs could have negative health implications for patients. The IDEAL pharmacoeconomic analysis makes the case that drug cost savings from use of generic statins may be largely offset by higher patients care and indirect costs."

The results were presented at the annual American Heart Association Quality of Care and Outcomes Research Meeting in Washington, D.C., and a summary of the data was published in the current issue of "Circulation."

The newly announced American Heart Association (AHA) and American College of Cardiology (ACC) guidelines on secondary prevention further support LDL reduction. The new guidelines recommend that LDL-cholesterol should be less than 100 mg/dL for all patients with CHD and other forms of atherosclerosis vascular disease. In the IDEAL study, patients treated with Lipitor achieved average LDL-cholesterol levels of 81 mg/dL which was significantly lower than patients taking Zocor, who had an average LDL-cholesterol level of 104 mg/dL.

Lipitor is the most prescribed cholesterol-lowering therapy in the world, with nearly 115 million patient-years of experience.

Lipitor is a prescription drug. It is used in patients with multiple risk factors for heart disease such as family history, high blood pressure, age, low HDL or smoking to reduce the risk of heart attack and stroke. When diet and exercise alone are not enough, Lipitor is used along with a low-fat diet and exercise to lower cholesterol.

Lipitor is also used in patients with type 2 diabetes and at least one other risk factor for heart disease such as high blood pressure, smoking or complications of diabetes, including eye disease and protein in urine, to reduce the risk of heart attack and stroke.

For additional product information, visit https://www.lipitor.com/.

Source: Pfizer

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs